7 completed. 7 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 1 | Completed 1 |
Follow Craniosynostoses: new trials by email Literature Review of Craniosynostoses trials Research Report on Craniosynostoses
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer Erdafitinib Intravesical Delivery System - Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 5 | 2023-03-03 | 2026-11-03 |
| A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer E7090, Fulvestrant, Exemestane - Breast Neoplasms | Phase 1 | Completed | Eisai Co., Ltd. | 51 | 2020-10-09 | 2026-07-17 |
| Derazantinib and Atezolizumab in Patients With Urothelial Cancer Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily+ atezolizumab 1200 mg - Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | Basilea Pharmaceutica | 95 | 2019-08-02 | 2023-10-13 |
| A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102) Pemigatinib - Solid Tumors | Phase 1 | Completed | Incyte Corporation | 44 | 2017-08-01 | 2020-05-29 |
| Phase 1b Trial of BGJ398/BYL719 in Solid Tumors BGJ398, BYL719 - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 62 | 2013-10-01 | 2020-12-09 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma JNJ-42756493: Part 1, JNJ-42756493: Part 2, JNJ-42756493: Part 3 - Tumor or Lymphoma | Phase 1 | Completed | Janssen Research & Development, LLC | 188 | 2012-06-15 | 2025-02-03 |
| Amicar Pharmacokinetics of Children Having Craniofacial Surgery Epsilon-Aminocaproic Acid - Craniosynostosis | Phase 1 | Completed | Paul Stricker | 18 | 2009-05-01 | 2012-11-01 |
Acrocephalosyndactylia (6) · Breast Neoplasms (2) · Neoplasms (2) · Urinary Bladder Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Lymphoma (1) · Small Cell Lung Carcinoma (1)
Bone Diseases (7) · Bone Diseases, Developmental (7) · Congenital Abnormalities (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Craniofacial Abnormalities (7) · Dysostoses (7) · Musculoskeletal Abnormalities (7) · Musculoskeletal Diseases (7) · Synostosis (7) · Limb Deformities, Congenital (6) · Syndactyly (6) · Neoplasms by Site (5) · Neoplasms (4) · Breast Diseases (2)
Alpelisib (1) · Aminocaproic Acid (1) · Fulvestrant (1) · atezolizumab (1) · derazantinib (1) · erdafitinib (1) · exemestane (1) · infigratinib (1) · pemigatinib (1)
Basilea Pharmaceutica (1) · Eisai Co., Ltd. (1) · Incyte Corporation (1) · Janssen Pharmaceutical K.K. (1) · Janssen Research & Development, LLC (1) · Novartis Pharmaceuticals (1) · Paul Stricker (1)
United States (4) · France (3) · Japan (3) · Spain (3) · Australia (2) · Canada (2) · Germany (2) · Italy (2) · South Korea (2) · Switzerland (2) · Austria (1) · Belgium (1) · Czechia (1) · Hungary (1) · Netherlands (1)
Ekaterine Asatiani, MD (1) · Paul Stricker, MD (1)
PMID 26324363, PMID 31088831, PMID 31280362, PMID 38627238
2019 (1)